10Q Summary:
Samsung:
The bad:
We owe $13.5M and were notified by Samsung to make commercially reasonable efforts. Samsung MAY terminate the agreement within 45 days.
The good: Management notified them in writing their intent to commence the agreement before day 45.
The ugly: Manipulators love this. They will pound this narrative forever and try and put the company in a hostile environment on why they’re not answering to share holders.
The truth: Samsung has liked the Covid-19 results in the past and understands the commercial value of Leronlimab.
Personal belief: I don’t think Samsung terminates the contract. I believe there will be a new arrangement made to keep both parties in a relationship.
Sec:
The bad: Posters at YMB have claimed they reached out to SEC about comments. In the 10Q it now lists mTNBC. The last person I remember doing this with the SEC (to the best of my ability) was affiliated with IncellDx and had 200K promissory notes with them.
The Good: the company has previous PRs comparing the approved mTNBC drug and the chemotherapy data. We just need significant data soon.
The ugly: Manipulators will demand to see the data.
The truth: It “could” be a new application and it MAY be 60 days. We will find out soon. However, many share holders note that we are shooting ourselves in the foot. Maybe some share holders are impatient, maybe some are not actual share holders and they want to know the data, so big pharma can manipulate theirs to keep extending the goal post. Bottom line is, the FDA said our drug is slightly better than an approved drug in Oncology that was bought for $21B. Shareholders know that’s just (1) of our 32+ indications.
Amarex:
The bad: we already know they screwed us. And now we may have in question of a $6.5M bond, something that could be delayed for several months if the company doesn’t have it.
The good: Naders proactive video was really him being proactive. He said we had about $8M and the last time he re-assured us, we didn’t go bankrupt at the end of the year. A loss the narrative was told all year didn’t happen.
The ugly: They will continue to use the bankruptcy narrative.
The truth: We have 187-200M shares to raise money and pay everyone.
Nash:
The good: “In November and December 2021, interim preliminary results were announced regarding the Company’s Phase 2 NASH, 14-week open-label, 350 mg weekly dose, clinical trial. In January 2022, the Company announced it met its primary endpoint in proton density fat fraction (“PDFF”) and its secondary endpoint in cT1 in this trial. This clinical trial compared the changes from baselines in these endpoints in 22 patients.”
The ugly: Manipulators said we didn’t hit end points when we did. They claimed the company didn’t announce 700Mg results because the results were bad.
The truth: Historically, 700Mg have yielded better results than 350Mg. Also, WE DON’T HAVE THE RESULTS YET. “The Company is evaluating the results of the other part of the trial, in which 50 patients received a 700 mg weekly dose of either leronlimab or a placebo in a double-blind, randomized”
Personal belief: I feel we are raising money as little as possible. We only want to have about $6-10M on hand. The reason is because once we potentially get an approval, we will have the ability to buy back a huge amount of our shares so the dilution is minimal and then we will still have about 100M to negotiate partnerships.
Highlights:
“The Company believes that material uncertainties related to the ultimate regulatory approval of leronlimab for commercial sale have been significantly reduced”
"Revenue recognized was approximately $225.0 thousand and $266.0 thousand for the three and six months ended November 30, 2021, respectively..." (est $491K)
“In December 2021, the Company hired Darshana Jani, M.S., as Vice President, Clinical Biosciences, who has over 25 years of industry experience in pharmaceutical drug development, including designing and developing a variety of regulatory compliant biological and bioanalytical methods and assay platforms in therapeutic areas for hematology, oncology, neurology, and auto-immune disease. She has successfully contributed to numerous IND and BLA submissions in the U.S. and internationally”
This lady sounds like our female version of Chris Recknor. We drafted another MVP.
Last but not least: “The Company intends to seek additional funding through equity or debt offerings, licensing agreements, supply and distribution agreements, and strategic alliances to implement its business plan.“
The last proactive video, NP said he would go Fund Raise. Go NASH!
Samsung:
The bad:
We owe $13.5M and were notified by Samsung to make commercially reasonable efforts. Samsung MAY terminate the agreement within 45 days.
The good: Management notified them in writing their intent to commence the agreement before day 45.
The ugly: Manipulators love this. They will pound this narrative forever and try and put the company in a hostile environment on why they’re not answering to share holders.
The truth: Samsung has liked the Covid-19 results in the past and understands the commercial value of Leronlimab.
Personal belief: I don’t think Samsung terminates the contract. I believe there will be a new arrangement made to keep both parties in a relationship.
Sec:
The bad: Posters at YMB have claimed they reached out to SEC about comments. In the 10Q it now lists mTNBC. The last person I remember doing this with the SEC (to the best of my ability) was affiliated with IncellDx and had 200K promissory notes with them.
The Good: the company has previous PRs comparing the approved mTNBC drug and the chemotherapy data. We just need significant data soon.
The ugly: Manipulators will demand to see the data.
The truth: It “could” be a new application and it MAY be 60 days. We will find out soon. However, many share holders note that we are shooting ourselves in the foot. Maybe some share holders are impatient, maybe some are not actual share holders and they want to know the data, so big pharma can manipulate theirs to keep extending the goal post. Bottom line is, the FDA said our drug is slightly better than an approved drug in Oncology that was bought for $21B. Shareholders know that’s just (1) of our 32+ indications.
Amarex:
The bad: we already know they screwed us. And now we may have in question of a $6.5M bond, something that could be delayed for several months if the company doesn’t have it.
The good: Naders proactive video was really him being proactive. He said we had about $8M and the last time he re-assured us, we didn’t go bankrupt at the end of the year. A loss the narrative was told all year didn’t happen.
The ugly: They will continue to use the bankruptcy narrative.
The truth: We have 187-200M shares to raise money and pay everyone.
Nash:
The good: “In November and December 2021, interim preliminary results were announced regarding the Company’s Phase 2 NASH, 14-week open-label, 350 mg weekly dose, clinical trial. In January 2022, the Company announced it met its primary endpoint in proton density fat fraction (“PDFF”) and its secondary endpoint in cT1 in this trial. This clinical trial compared the changes from baselines in these endpoints in 22 patients.”
The ugly: Manipulators said we didn’t hit end points when we did. They claimed the company didn’t announce 700Mg results because the results were bad.
The truth: Historically, 700Mg have yielded better results than 350Mg. Also, WE DON’T HAVE THE RESULTS YET. “The Company is evaluating the results of the other part of the trial, in which 50 patients received a 700 mg weekly dose of either leronlimab or a placebo in a double-blind, randomized”
Personal belief: I feel we are raising money as little as possible. We only want to have about $6-10M on hand. The reason is because once we potentially get an approval, we will have the ability to buy back a huge amount of our shares so the dilution is minimal and then we will still have about 100M to negotiate partnerships.
Highlights:
“The Company believes that material uncertainties related to the ultimate regulatory approval of leronlimab for commercial sale have been significantly reduced”
"Revenue recognized was approximately $225.0 thousand and $266.0 thousand for the three and six months ended November 30, 2021, respectively..." (est $491K)
“In December 2021, the Company hired Darshana Jani, M.S., as Vice President, Clinical Biosciences, who has over 25 years of industry experience in pharmaceutical drug development, including designing and developing a variety of regulatory compliant biological and bioanalytical methods and assay platforms in therapeutic areas for hematology, oncology, neurology, and auto-immune disease. She has successfully contributed to numerous IND and BLA submissions in the U.S. and internationally”
This lady sounds like our female version of Chris Recknor. We drafted another MVP.
Last but not least: “The Company intends to seek additional funding through equity or debt offerings, licensing agreements, supply and distribution agreements, and strategic alliances to implement its business plan.“
The last proactive video, NP said he would go Fund Raise. Go NASH!
30
1
